Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results cons ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback